• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study.

作者信息

Hirai Toshinori, Ino Kazuko, Ikejiri Makoto, Tawara Isao, Iwamoto Takuya

机构信息

Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Department of Hematology and Oncology, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

出版信息

Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):889-893. doi: 10.1007/s13318-022-00790-9. Epub 2022 Aug 17.

DOI:10.1007/s13318-022-00790-9
PMID:35978155
Abstract
摘要

相似文献

1
Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study.伏立康唑和克拉霉素对CYP3A4的双重抑制作用影响他克莫司的药代动力学：病例系列研究
Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):889-893. doi: 10.1007/s13318-022-00790-9. Epub 2022 Aug 17.
2
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems.克拉霉素和酮康唑对不同 CYP3A4 基因型重组代谢酶系统中 FK506 代谢的影响。
Curr Drug Metab. 2024;25(2):174-177. doi: 10.2174/0113892002286019240315052145.
3
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.CYP3A 和 ABCB1 单核苷酸多态性对钙调神经磷酸酶抑制剂的药代动力学和药效学的影响：第二部分。
Clin Pharmacokinet. 2010 Apr;49(4):207-21. doi: 10.2165/11317550-000000000-00000.
4
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.CYP3A药物遗传学与成人心脏移植受者中环孢素A的处置
Clin Transplant. 2016 Sep;30(9):1074-81. doi: 10.1111/ctr.12790. Epub 2016 Jul 11.
5
Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.供体肝脏CYP3A4*20功能缺失基因型对移植患者他克莫司药代动力学的影响。
Pharmacogenet Genomics. 2018 Feb;28(2):41-48. doi: 10.1097/FPC.0000000000000321.
6
Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.克拉霉素联合伏立康唑通过协同抑制CYP3A4过度增强钙通道阻滞剂作用导致急性肾损伤
Intern Med. 2017;56(13):1687-1690. doi: 10.2169/internalmedicine.56.8313. Epub 2017 Jul 1.
7
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.CYP3A 和 ABCB1 单核苷酸多态性对钙调神经磷酸酶抑制剂的药代动力学和药效学的影响：第一部分。
Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000.
8
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.儿童肾病综合征个体化他克莫司治疗：CYP3A 个体发育和药物遗传学的考虑因素。
Curr Pharm Des. 2018;24(24):2765-2773. doi: 10.2174/1381612824666180829101836.
9
Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.ABCB1、CYP3A4*18B 和 CYP3A5*3 基因型与他克莫司在健康中国受试者中的药代动力学的相关性：群体药代动力学分析。
J Clin Pharm Ther. 2011 Oct;36(5):614-24. doi: 10.1111/j.1365-2710.2010.01206.x. Epub 2010 Oct 5.
10
The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.在心脏移植受者中，与伏立康唑合用时，CYP2C19 基因型对他克莫司剂量优化的重要性。
Br J Clin Pharmacol. 2022 Oct;88(10):4515-4525. doi: 10.1111/bcp.15385. Epub 2022 May 16.

引用本文的文献

1
Pharmacokinetic Model of Drug Interaction of Tacrolimus with Combined Administration of CYP3A4 Inhibitors Voriconazole and Clarithromycin After Bone Marrow Transplantation.移植术后环孢素与 CYP3A4 抑制剂伏立康唑和克拉霉素联合应用的药物相互作用的药代动力学模型。
Eur J Drug Metab Pharmacokinet. 2024 Nov;49(6):763-771. doi: 10.1007/s13318-024-00915-2. Epub 2024 Sep 24.
2
Pharmacokinetic interaction of voriconazole and clarithromycin in Pakistani healthy male volunteers: a single dose, randomized, crossover, open-label study.伏立康唑与克拉霉素在巴基斯坦健康男性志愿者中的药代动力学相互作用：一项单剂量、随机、交叉、开放标签研究。
Front Pharmacol. 2023 Jun 9;14:1134803. doi: 10.3389/fphar.2023.1134803. eCollection 2023.

本文引用的文献

1
Drug-Drug-Gene Interactions: A Call for Clinical Consideration.药物-药物-基因相互作用：呼吁临床予以考虑。
Clin Pharmacol Ther. 2021 Sep;110(3):549-551. doi: 10.1002/cpt.2348. Epub 2021 Jul 18.
2
Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review.成人移植受者他克莫司的群体药代动力学模型：系统评价。
Clin Pharmacokinet. 2020 Nov;59(11):1357-1392. doi: 10.1007/s40262-020-00922-x.
3
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.他克莫司治疗药物监测-个体化治疗：第二版共识报告。
Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.临床药物遗传学实施联盟（CPIC） CYP2C19 和伏立康唑治疗指南。
Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18.
5
Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.肝移植术后早期每日一次剂量他克莫司的药代动力学：特别参考CYP3A5和ABCB1单核苷酸多态性
Ann Transplant. 2016 Aug 9;21:491-9. doi: 10.12659/aot.898358.
6
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.伏立康唑的剂量依赖性生物利用度和CYP3A抑制作用导致其非线性药代动力学。
Clin Pharmacokinet. 2016 Dec;55(12):1535-1545. doi: 10.1007/s40262-016-0416-1.
7
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.细胞色素P450 2C19基因多态性对与伏立康唑合用时他克莫司药代动力学的影响。
J Clin Pharmacol. 2016 Apr;56(4):408-13. doi: 10.1002/jcph.605. Epub 2015 Oct 8.
8
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.克拉霉素对肠道壁和肝 CYP3A 的抑制作用的起始速度。
Eur J Clin Pharmacol. 2013 Mar;69(3):439-48. doi: 10.1007/s00228-012-1339-x. Epub 2012 Jul 10.
9
Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.异烟肼和他克莫司之间的药物相互作用及其与异烟肼口服生物利用度的关系在异基因造血干细胞移植受者中。
Int J Hematol. 2012 May;95(5):564-9. doi: 10.1007/s12185-012-1057-2. Epub 2012 Mar 30.
10
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.基于生理学的克拉霉素对 CYP3A 机制性抑制的药代动力学模型。
Drug Metab Dispos. 2010 Feb;38(2):241-8. doi: 10.1124/dmd.109.028746. Epub 2009 Nov 2.